Close Menu

NEW YORK – Clinical-stage biopharma company Oncologie said on Tuesday that it is collaborating with Moffitt Cancer Center to develop oncology treatments targeting the tumor microenvironment (TME).

In the partnership, Moffitt will utilize Oncologie's bioinformatics platform of RNA signatures to analyze the tumor microenvironments of patients with gastric and gastrointestinal cancer, then use that to classify tumors as well as evaluate correlations to treatment response and outcomes.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.